Phase I/II, open-label, multicenter, safety, efficacy and PK study of a recombinant coagulation factor IX albumin fusion protein (rIX-FP) in subjects with hemophilia B
Keywords: Hemophilia B; Factor IX; Albumin fusion protein; Pharmacokinetics; Recombinant albumin; PROLONG-9FPAE, adverse event; AUC, area under the curve; EOS, end of study; FIX, factor IX; IR, incremental recovery; pdFIX, plasma-derived FIX; PK, pharmacokinetic; r